PO13 | OUTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM AND SUBSEQUENT RISK OF CANCER
S. Sørensen, D. Farkas, H. Sørensen | Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction. Venous thromboembolism (VTE) patients with a low risk of complications are increasingly being treated on an outpatient basis. VTE is a known marker for occult cancer, but the risk of malignancy is only known to a limited extent in VTE patients treated on an outpatient basis.
Aim. To examine the risk of cancer after hospital-based outpatient treatment of VTE.
Materials and Methods. For 2000-2022 we used Danish health registries to include all patients treated for VTE in a hospital-based outpatient setting (including emergency room visits) who did not have an inpatient VTE hospitalization within 7 days of diagnosis. VTE patients with fewer than 7 days of follow-up were excluded. Patients were followed from 7 days after their outpatient VTE treatment to first incident of cancer (except non-melanoma skin cancer), death, emigration, or end of study (31 December 2022), whichever came first. As measures of relative cancer risks, we calculated age-, sex-, and calendar period-standardized incidence ratios (SIRs) comparing the observed cancer incidence among people with outpatient-treated VTE with the expected cancer incidence based on Danish national cancer rates.
Results. We identified 43,615 patients (50.6% female) with VTE who were treated in an outpatient setting. The median age was 61 years (interquartile range (IQR): 47-74) and the median follow-up time was 5.3 years (IQR: 2.3-10.3). During the first year of follow-up, 1,275 were diagnosed with cancer, yielding an SIR of 2.58 (95% confidence interval (CI): 2.44 – 2.73). During the first year of follow-up, SIRs exceeding 4 for cancer sites with more than 10 observed cases were observed for liver, gallbladder, pancreatic, cervical, ovarian, and thyroid cancers, as well as non-Hodgkin lymphoma. During the subsequent years, the SIR declined to 1.18 (95% CI: 1.15–1.22).
Conclusions. VTE is a marker of undiagnosed cancer in patients treated for VTE on an outpatient basis.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC05 | TIME TO START OF ANTICOAGULANT THERAPY AND SURVIVAL OUTCOMES IN CANCER PATIENTS WITH PULMONARY EMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
